Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Weekly Buzzing Stocks by Billy Kawasaki and The Panic-Proof Portfolio (Stockchase Research) commented about whether QSR-T, FMC-N, NVDA-Q, HPS.A-T, SFTC-T, BWLP-N, ZTS-N, HBM-T, BBU-N, ROIV-Q, SBUX-Q, LLY-N, SMCI-Q are stocks to buy or sell.
- Page 1/3
- Next Page
- Super Micro Computer (SMCI-Q)
- Eli Lilly & Co. (LLY-N)
- Regions Financial (RF-N)
- Starbucks (SBUX-Q)
- NVIDIA Corporation (NVDA-Q)
- Microsoft Corp (MSFT-Q)
- Reddit Inc. (RDDT-N)
- MicroStrategy (MSTR-Q)
- Trump Media & Technology Group (DJT-Q)
- AbbVie Inc. (ABBV-N)
- Coca-Cola Company (KO-N)
- Altria Group Inc (MO-N)
- Main Street Capital Corp. (MAIN-N)
- FuelCell Energy (FCEL-Q)
- Cardiol Therapeutics (CRDL-T)
Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high-performance server and storage solutions based on modular and open architecture. Its solutions range from complete server, storage, modular blade servers, blades, workstations, full racks, networking devices, server management software, and server sub-systems, as well as support and services. The company also provides application-optimized server solutions, including rackmount and blade servers, storage systems, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. Social media mentions are up 225% in the past 24h.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Social media mentions are up 282% in the past 24h.
Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington. Social media mentions are up 167% in the past 24h.
We reiterate ROIV as a TOP PICK. The pharma company has continued to increase R&D spending into drugs for treatment such as autoimmune issues respiratory hypertension. It trades at 2x trailing earnings and 1.6x book value, while supporting a robust return on equity. We like that cash reserves are growing, while debt is retired. We recommend maintaining the stop at $10.50, looking to achieve $15.00 -- upside potential of 27%. Yield 0%
(Analysts’ price target is $17.06)We reiterate this Canadian based private equity company as a TOP PICK. Its investments are generally majority owned and internationally based, looking for capital returns in excess of 15% annually -- demonstrating the expertise of management. We like that cash reserves are growing as debt is retired and shares bought back. It trades at 17x earnings, under book value and supports a 20% ROE. We continue to recommend a stop at $19, looking to achieve $28 -- upside potential of 27%. Yield 1.1%
(Analysts’ price target is $30.86)We reiterate this Canadian producer of copper and gold with holdings extending into South America as a TOP PICK. We like that cash reserves are growing, while debt is retired. It trades at 11x earnings and 1.5x book. We recommend trailing up the stop (from $9) to $10, looking to achieve $16 -- upside potential of 27%. Yield 0.1%
(Analysts’ price target is $16.40)Our PAST TOP PICK with SFTC has triggered its stop at $18. To remain disciplined, we recommend covering the position at this time. When combined with previous guidance, this will result in a net investment gain of 12%
Finally at the precipice. The Fed and BOC have both cut interest rates. Research shows that from the beginning of the Fed's easing cycle real estate stocks, on average, outperform -- up 20% over 2 years, up 30% over 3 years. Couple that with the publicly traded real estate sector being the most underweighted in history. Though you have to look at each sub-sector, it's a pretty compelling setup on fundamentals for both sides of the border.
